• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SVB Leerink initiated coverage on Selecta Biosciences with a new price target

    6/6/22 7:48:05 AM ET
    $SELB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SELB alert in real time by email
    SVB Leerink initiated coverage of Selecta Biosciences with a rating of Outperform and set a new price target of $7.00
    Get the next $SELB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SELB

    DatePrice TargetRatingAnalyst
    8/18/2023$1.00Outperform → Market Perform
    SVB Securities
    6/14/2022$6.00 → $5.00Buy
    Needham
    6/6/2022$7.00Outperform
    SVB Leerink
    11/1/2021$6.00 → $7.00Buy
    Needham
    More analyst ratings

    $SELB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

      Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase 2a study in MG reported today; durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores observed approximately 10 months after last infusion Phase 2 study of Descartes-08 in systemic lupus erythematosus expected to initiate in 1H24 Clinical pipeline expanded following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate Approximately $118M pro forma cash and cash equivalents as of D

      1/8/24 7:10:00 AM ET
      $RNAC
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

      Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 observed to be well tolerated following administration in outpatient setting Publication is in peer review and available on the preprint server, medRxiv Topline data from Phase 2b placebo-controlled study continues to be expected in mid-2024 GAITHERSBURG, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC), ("the Company") a clinical-stage biotechnology company pioneering mRNA cell therap

      1/8/24 7:00:00 AM ET
      $RNAC
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Announces Merger with Cartesian Therapeutics

      – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen

      11/13/23 8:05:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Singer Michael was granted 178,000 units of Common Stock, increasing direct ownership by 162% to 288,123 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:12:27 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Davis Blaine was granted 2,424,000 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:29 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jewell Christopher M was granted 778,200 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:06 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care